Trial · NCT07881588
Construction and Empirical Research of a Risk Prediction Model for Preventing Lower Extremity Arteriosclerosis Obliterans in Diabetic Patients Based on the HAPA Model
NCT07881588, Not applicable, Recruiting, Second Affiliated Hospital of Nanchang University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Construction and Empirical Research of a Risk Prediction Model for Preventing Lower Extremity Arteriosclerosis Obliterans in Diabetic Patients Based on the HAPA Model. Trials, record NCT07881588. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07881588
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Construction and Empirical Research of a Risk Prediction Model for Preventing Lower Extremity Arteriosclerosis Obliterans in Diabetic Patients Based on the HAPA Model
- NCT number
- NCT07881588
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 154 participants, estimated
- Lead sponsor
- Second Affiliated Hospital of Nanchang University
- Conditions
- Diabetes Mellitus, Peripheral Arterial Disease
- Interventions
- Routine Care, Experimental group intervention
- First posted
- 2026-10-19
- Last updated
- 2026-10-19
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | ankle brachial index, ABI | Collected respectively before the intervention and at 1, 3, and 6 months after the intervention | |
| Primary | Summary of Diabetes Self Care Activities, SDSCA | Collected respectively before the intervention and at 1, 3, and 6 months after the intervention | This scale is used to assess the self-management ability of diabetic patients. It consists of 12 items, each of which is calculated on an 8-point scale ranging from 0 to 7. Individuals choose a score of 0 to 7 based on the number of days they have implemented it. The higher the score, the better the self-management ability. A score of 80 or above indicates good self-management ability, 60 to 80 indicates medium self-management ability, and below 60 indicates poor self-management ability. |
| Secondary | Diabetes Specific Quality of Life Scale, DSQL | Collected respectively before the intervention and at 1, 3, and 6 months after the intervention | DSQL is a specific quality of life scale designed for Chinese diabetic patients, consisting of 27 items in four dimensions: physiological, psychological, social and therapeutic. The total score ranges from 27 to 135 points. The higher the score, the worse the quality of life. The reference cut-off values are as follows: a score below 54 is considered good, 55 to 81 is medium, and a score above 82 indicates a poor quality of life. This scale has good reliability, validity and responsiveness, and is suitable for evaluating the current quality of life and intervention effects of Chinese diabetic patients. |
| Secondary | The Third Version of Diabetes Attitude Scale, DAS-3 | Collected respectively before the intervention and 1, 3, and 6 months after the intervention | The DAS-3 scale consists of five dimensions: Professional training needs, severity of type 2 diabetes, the value of strict blood sugar control, psychosocial impact and patient autonomy were scored using a 5-point Likert scale (1= strongly disagree, 5= strongly agree). Among them, the reverse scoring items needed to be converted to 6 minus the original score. The final score of each dimension was the average score of all items processed under that dimension. The higher the score, the more positive the attitude and the more in line with modern diabetes management concepts |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07881588
GET https://conductscience.org/api/trials/v1/NCT07881588/registered